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Summary The prognostic role of drug-induced amenorrhea (DIA) was restrospectively evaluated in 221 out
of 254 consecutive premenopausal patients treated with adjuvant CMF or a CMF-containing regimen; 33
patients were eliminated because of lack of menstrual data. All patients had metastatic axillary nodes; drug
regimens were: CMF x 9 courses ±Tamoxifen (TM) and CMF x 6 courses; median age was 43 (range 26-54).
Premenopausal status was defined as last normal menses within the 6 weeks preceding initiation of
chemotherapy; DIA as cessation of menses for at least 3 months not later than 3 months from the end of
chemotherapy. DIA occurred in 166/221 (75.1%) patients and was strictly related to the age of the patients;
also, the older the patients the shorter the time required to develop DIA. At median follow up of 69 months,
Mantel-Byar analysis showed a longer disease free survival (DFS) for patients who developed DIA as
compared with non amenorrheic women (P<0.001). DIA prognostic value was independent of age, number
of involved nodes, tumour size and number of CMF cycles, as assessed by the Cox model (RH 0.43, 95% C.I.
0.24-0.77), in which DIA was entered as a time dependent covariate.
Adjuvant chemotherapy, especially cyclophosphamide, metho-
trexate and 5-fluorouracil (CMF), has been shown to signifi-
cantly increase disease-free survival and overall survival of
premenopausal patients with operable breast cancer (Bona-
donna et al., 1985; Early Breast Cancer Trialists' Collabor-
ative Group, 1988).
In similar groups of patients, surgical oophorectomy and
ovarian radiation, as adjuvant to mastectomy, were also
effective in reducing relapses and deaths (Nissen-Meyer,
1967; Bryant et al., 1981; Meakin et al., 1983).
Since cytotoxic chemotherapy is more effective in premeno-
pausal than in postmenopausal patients (Early Breast Cancer
Trialists' Collaborative Group, 1988) and, in many cases, it
induces ovarian failure with the occurrence of amenorrhea, a
question arises about the relationship between the effect of
adjuvant chemotherapy and the development of amenorrhea.
In fact it has been suggested that drug-induced amenorrhea
has beneficial therapeutic significance and that the effect of
adjuvant chemotherapy is mediated, at least partly, through
the suppression of endogenous hormone production.
While an association between drug-induced amenorrhea
and longer disease free survival has been found by several
authors in premenopausal patients with early breast cancer
(Ludwig Breast Cancer Study Group, 1985; Padmanabhan et
al., 1986; Brincker et al., 1987; Tormey et al., 1990), others
have failed to do so (Bonadonna et al., 1985; Fisher et al.,
1979), and thus the question remains still open (Editorial,
1989).
The aim of our study was to evaluate, restrospectively, if
the development of drug-induced amenorrhea is associated
with a prolongation of DFS in a series of consecutive cases
of homogeneous premenopausal, node-positive patients with
early breast cancer, treated with adjuvant CMF-containing
regimens between 1978 and 1989.
Patients and methods
Selection criteria
The study included premenopausal women with histologically
confirmed, non inflammatory unilateral stage II or III(T3a)
operable breast cancer.
Premenopausal status was defined by the occurrence of the
last normal menses within the 6 weeks preceding initiation of
adjuvant chemotherapy.
Primary treatment was radical or modified radical mastec-
tomy or quadrantectomy followed by radiotherapy of resid-
ual breast in small (TI) tumours. All patients had metastatic
axillary nodes (N + ).
Three adjuvant CMF containing regimens were employed:
(a) CMF for nine courses plus Tamoxifen (TM), 30 mgday-'
for 2 years; (b) CMF alone for nine courses; (c) CMF alone
for six courses. The CMF regimen was cyclophosphamide
100 mg m-2 orally on days 1-14, methotrexate 40 mg m-2
and 5-fluorouracil 600 mgm-2 intravenously on days 1 and 8
of each 28 day cycle. Patients were eligible for adjuvant
chemotherapy if white blood cell count was 4 x 1091-' or
more, platelet count 100 x IO' -' or more and serum creatin-
ine, bilirubin and aminotransferase were within normal levels.
Sixty-eight percent of patients were enrolled in two con-
trolled clinical trials; one of which has been previously
reported (Bianco et al., 1988).
Definition ofamenorrhea
Patients were considered to have drug-induced amenorrhea
(DIA) ifcessation of menses occurred no later than 3 months
from the completion ofchemotherapy, and lasted for at least
3 months; the first day of the last menstrual cycle was taken
as the time of onset of amenorrhea. Amenorrheic patients
who resumed some menstrual function during follow up have
been defined as temporary-DIA.
Patients who maintained normal menses beyond 3 months
after the end of chemotherapy, were considered non amenor-
rheic (NA).
Details ofpatients
From February 1, 1978 to March 1, 1989, 259 consecutive
patients were included into the study.
Thirty-eight patients were not evaluable for the analysis: in
28 the menstrual history was incomplete, two patients had
uncertain records of the beginning and ending oftherapy and
eight patients refused the assigned adjuvant treatment. Thus,
221 patients were analysed. The main characteristics of the
patients are summarised -in Table I. Median age was 43
(range 26-54). CMF-9 cycles ± TM (56 and 57 patients,
respectively) were the two arms of a randomised controlled
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Table I Characteristics of patients
Variable No. %
Total number 221
Age
< 35 28 12.7
36-40 39 17.6
41-45 75 33.9
46-50 61 27.6
>50 18 8.1
Positive nodes
1-3 105 47.5
>3 116 52.5
Tumour size
<2 cm 46 20.8
2.1-5 cm 121 54.8
>5cm 27 12.2
unknown 27 12.2
Adjuvant therapy
CMF-9 cycles ±TM 113 51.1
CMF-6 cycles 108 48.9
trial (Bianco et al., 1988), and no difference was found in
DFS between the two treatment groups. Thus, in the present
study, they have been considered equivalent and two classes
of length of therapy have been defined: nine and six CMF
cycles.
Statistical methods
Starting date for the follow up was initiation of CMF
therapy. Termination date for the analysis was March 1st,
1990, when the median follow up was 69 months.
DFS was defined as the time from beginning of therapy to
when either recurrent disease was ascertained or was suspect-
ed and later confirmed. Failure was defined as any first
recurrence including contralateral disease; no death was
observed without recurrence. Time to amenorrhea was the
interval between the date of the last menstrual cycle and the
beginning of CMF therapy; when negative values were
observed, as a consequence of the definition of DIA, a shift
to the first day following initiation of therapy was done.
Kaplan-Meier method (1958) was used to estimate DFS
curves for baseline prognostic factors; statistical significance
of DFS difference was assessed by Mantel-Haenszel test
(Mantel, 1966). In studying amenorrhea, life-time analyses
were performed taking into account the transient nature of
the menstrual status: cessations of menses, indeed, as conse-
quence of the therapy, do arise at a sometime after the
starting of the treatment. Thus, a potential temporal bias
exists in classifying a subject as amenorrheic or not, since the
length of disease-free follow up could affect the chance of
amenorrhea to be induced (Anderson et al., 1983). Even
though the magnitude of the bias is likely to be small,
because most of DIA occur shortly after the therapy, an
appropriate analysis was performed using a method first
published by Mantel and Byar (1974), in which subjects
(amenorrhea yes/no) are compared according to their re-
sponse status at each time of the follow up. Graphical repre-
sentation of DFS curves was made according to Simon and
Makuch (1984): non relapsed subjects at a given arbitrary
time-origin to. from the beginning of follow up, are classified
in two groups according to whether they have or have not
experienced DIA before to. For the non amenorrheic group,
DFS curve estimates the probability of not relapsing beyond
any time tj, greater than t., conditional upon being in NA
status at to; subjects who eventually became amenorrheic are
censored at the time they cross to the DIA group. For
amenorrheic ('responders') patients, DFS curve estimates the
probability of not relapsing beyond tj, tj>t., given either
they are in DIA status at to or enter it in the interval between
to and tj. As suggested by Simon and Makuch, in our study,
to was fixed at 12 weeks after the onset of therapy, when
more than half of patients had experienced DIA. For exam-
ple, a patient who develops amenorrhea at 8 weeks is always
considered to have been amenorrheic, from the 12th week (to)
until relapse or last follow up. Conversely a patient who
becomes amenorrheic at 36 weeks remains in the non-amen-
orrheic group from 12 weeks (to) to 36 weeks, when she is
censored. This same patient is then considered in the amenor-
rheic group from the time of development of amenorrhea
until relapse or last follow up. In the 'landmark' method
(Anderson et al., 1983), instead, groups are defined according
to the menstrual status at a given 'landmark' time to, regard-
less of any subsequent variation during the follow up. In our
study no relapse was observed before to time; therefore no
patient was excluded from the computations.
Multivariate adjustment for other baseline prognostic fac-
tors was performed by a Cox's regression model (Cox, 1972),
where amenorrhea (yes/no) was entered as a time-dependent
covariate (BMDP, 1988).
Results
Amenorrhea occurred in 166/221 (75.1%) patients. Twenty
amenorrheic patients (12%) resumed some menstrual activity
between 4 and 29 months after cessation of menses (tem-
porary DIA). Time to onset of DIA ranged between -21 and
342 days from the beginning of cytotoxic chemotherapy
(median 53 days). Negative values refer to eight patients,
aged 43-53, who had their last menstrual cycle 21 to 5 days
before the starting of therapy.
No significant correlation was found between DIA and
number of involved axillary nodes or tumour size, while
occurrence of amenorrhea was significantly associated with
number of CMF cycles (Table II).
A significant correlation was also found between the
development of amenorrhea and the patient's age: the young-
er the patients the lower the incidence of DIA. Among
amenorrheic patients a decreasing percentage of temporary
DIA was observed with increasing age. Furthermore, an
inverse linear correlation (Figure 1) was observed between
the patient's age and the time required to produce amenor-
rhea (r = -0.42; P<0.001).
One hundred and two relapses were observed during the
follow up.
DFS of amenorrheic patients was significantly better than
that of patients who maintained normal menses (Mantel-
Byar chi-square = 10.95, P<0.001; relative hazard = 0.50).
DFS curves for DIA and NA patients, as shown in Figure 2,
take into account the time-dependent nature of menstrual
status according to Simon and Makuch. Time-origin is arbi-
trarly fixed at 12 weeks after the beginning of treatment. At
that time, 121 out of the 166 DIA subjects (72.9%) had
already become amenorrheic.
Table II Association between drug-induced amenorrhea and other
patient variables
Variable NA DIA P
Temporary Permanent
No. ofcases (%)
Age <0.0001
S35 25 (89.3) 3 (10.7)
36-40 21 (53.8) 5 (12.8) 13 (33.3)
41-45 6 ( 8.0) 9 (12.0) 60 (80.0)
46-50 1 (1.6) 3 ( 4.9) 57 (93.4)
>50 2 (11.1) 16 (88.9)
No. of positive 0.21
nodes
1-3 25 (23.8) 6 ( 5.7) 74 (70.5)
>3 30 (25.9) 14 (12.1) 72 (62.1)
Tumour size 0.34
<2cm 9(19.6) 3 ( 6.5) 34(73.9)
2.1-5 cm 36 (29.8) 13 (10.7) 72 (59.5)
> 5 cm 6 (22.2) 3 (11.1) 18 (66.7)
unknown 4 (14.8) 1 ( 3.7) 22 (81.5)
No. of CMF cycles 0.002
9 cycles 17 (15.0) 13 (11.5) 83 (73.5)
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Table III DFS as related to prognostic variables
Variabk No. of Observed Expected OIE P
cases
0 60 120 180 240
Time (days)
300 360
Figure 1 Inverse linear correlation between the patient's age and
the time required to produce amenorrhea (r = -0.42; P<0.001).
i V~~~~
3 T
X 1 j.14 U i. e . t ' j.t W1 r
Figure 2@§ DFSt cuve fo D .A(e,t0,Fg ) ,, and no amenorrhic
pa gS..tients accordingto Sio an Makuc tim on horizontal T} fi$ .
axis is-expresse as numbers of yer fro t. (J )2t 12 wek ater{
the o.ns of therapy). M l B P3 1
X$r;iaw3L3;;~~~~~~~~~~~~~~~ ~ ~~~~~~~~~~~ Al A-ziaif* :iii
Figure 2 DFS curves for DIA ( )and non amenorrheic()
patients, according to Simon and Makuch: time on horizontal
axis is expressed as numbers of years from to (to= 12 weeks after
the onset of therapy). Mantel-Byar P<0.001.
Prognosis was also found to be associated with number of
positive nodes and tumour size, while no relationship was
apparent between DFS and age either considering 5 year cut
offs (Table III) or a single cut off at 40 years (age <40:
O/E = 1.28; age >40: O/E = 0.98; P = 0.08). Duration of
therapy (nine vs six CMF cycles) did not influence DFS.
Multivariate evaluation of the prognostic role of DIA was
performed by a Cox regression analysis, where menstrual
status was entered as a time-dependent covariate. Other co-
variates were age, number ofpositive nodes, tumour size and
number of CMF cycles (Table IV). DIA was confirmed to be
independently associated with a better prognosis (RH = 0.43;
95% CI 0.24-0.77). Number of positive nodes and tumour
size were also found to significantly affect DFS. No inter-
action was evident between menstrual status and other con-
ventional prognostic factors.
A similar analysis was performed to evaluate a possible
effect of DFS of resuming some mentrual activity during
follow up. Time-dependent analyses on the 166 amenorrheic
cases showed no difference in DFS between temporary and
permanent DIA patients (Mantel-Byar chi-square = 0.77,
0.30<P<0.40).
Discussion
The efficacy of adjuvant chemotherapy in reducing recur-
rences and deaths in premenopausal node positive breast
cancer patients has been confirmed in a number of studies.
However, it is still controversial if the benefit of cytotoxic
chemotherapy could be mediated, at least partly, by the drug
induced suppression of ovarian function.
Analysis and comparison of the data is difficult because of
a number of open questions in different studies.
First of all premenopausal status has been varyingly de-
Age
K35
36-40
41-45
46-50
>50
No. ofpositive
nodes
1-3
>3
Tumour size
<2cm
2.1-5 cm
>5cm
unknown
No. ofCMF cycles
9 cycles
6 cycles
28
39
75
61
18
105
116
18
19
31
24
10
34
68
12.5
16.5
35.6
30.3
7.1
54.6
47.4
46 17 28.7
121 55 52.9
27 17 1%1
27 13 1I0f.3
113 58 61.1
108 44 40.9
1.44
1.15
0.87
0.79
1.40
0.62
1.44
0.59
1.04
1.68
1.26
0.95
1.08
0.20
<0.0001
0.01
0.52
Table IV DFS as related to prognostic factors by multivariate
analysis
Covariate P RH (95% CI) P
Age
>40 vs <40 0.2009 1.22 (0.71-2.12) 0.47
No. positive nodes
>3 vs 1-3 0.8034 2.23 (1.45-3.44) 0.0002
Tumour size
2.1-5 cm vs <2 cm 0.3838 1.47 (0.84-2.58) 0.17
>5cm vs <2cm 0.8000 2.23 (1.09-4.55) 0.03
unknown vs <2 cm 0.6924 2.00 (0.95-4.22) 0.08
No. of CMF cycles
6 vs 9 cycles -0.0012 1.00 (0.64-1.55) 1.00
Menstrual status
DIA vs NA -0.8504 0.43 (0.24-0.77) 0.005
fined. Some studies (Bonadonna et al., 1985; Padmanabhan
et al., 1986; Tormey et al., 1990) used a rather wide criterion
to define premenopause which included women without men-
strual activity up to 12 months. The Ludwig Breast Cancer
Study Group (1985) evaluated the role of DIA in patients
who had their last menses within 6 months prior to initiation
of chemotherapy; however, a similar DFS was observed in
the subgroup of patients who had their last menses within 6
weeks prior to beginning of adjuvant chemotherapy. In order
to ensure that amenorrhea was drug-induced rather than
physiologic we adopted a restrictive criterion to define pre-
menopausal status such as the occurrence of the last normal
menses within the 6 weeks preceding the beginning of
therapy.
Another important aspect is the definition of DIA. We
believe that, in order to consider amenorrhea as drug-related,
this definition should be inclusive of both a minimum dura-
tion ofthe amenorrhea itselfand a defined period ofits onset
from the end of the therapy. While data are lacking on the
latter question, there is a general concordance (Fisher et al.,
1979; Bonadonna et al., 1985; Ludwig Breast Cancer Study
Group, 1985; Padmanabhan et al., 1986; Brincker et al.,
1987) in defining DIA as cessation of menses for at least 3
months, except for the Eastern Cooperative Oncology Group
(ECOG) study (Tormey et al., 1990) in which drug-related
amenorrhea is defined as 12 months without menstrual
activity.
In our study, as well as in others (Fisher et al., 1979;
Bonadonna et al., 1985; Ludwig Breast Cancer Study Group,
1985; Padmanabhan et al., 1986; Tormey et al., 1990), a close
relationship between induction of amenorrhea and age of the
patient is evident, the older the patient the greater the
incidence of DIA. Furthermore, we observed an inverse cor-
relation between the time to onset of DIA and patient's age.
These results seem to be the signal of the increasing ovarian
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sensitivity to cyclophosphamide in older women approaching
to physiological menopause, as suggested by Rose and Davis
(1980).
The variable definition of premenopausal status and DIA,
age distribution of patients and therapeutic regimens might
account for the wide range (32-87%) of DIA occurrence
reported in the literature (Fisher et al., 1979; Bonadonna et
al., 1985; Ludwig Breast Cancer Study Group, 1985; Pad-
manabhan et al., 1986; Brincker et al., 1987; Tormey et al.,
1990). In our study DIA occurred in 75% (166/221) of
patients, in 31 % of women 40 years or younger and in 94%
of those older than 40. Twenty patients (12%) resumed
normal menses after temporary DIA. Although temporary
DIA could be the expression of a partial suppression of
ovarian function, and thus associated with a different prog-
nosis, we did not find a significant difference in DFS among
amenorrheic patients with temporary and permanent DIA.
However, this result might be affected by the low number of
patients who resumed menses. Only the Ludwig Breast
Cancer Study Group (1985) dealt with this question, with
similar results.
Finally, the time dependent nature of amenorrhea might
somehow affect the correlation between DIA and DFS
(Anderson et al., 1983). This potential bias, however, is
probably small because of the general early occurrence of
cessation of menses following initiation of therapy. To over-
come this bias, in our study, we employed the Mantel-Byar
procedure (Mantel & Byar, 1974) in univariate analysis and
the Cox proportional hazard regression model (Cox, 1972) in
which amenorrhea is a time varying covariate, as it was done
in the ECOG study (Tormey et al., 1990).
The relationship between DIA and length of DFS was
analysed in several studies with conflicting results.
In the Milan trial (Bonadonna et al., 1985) only patients
younger than 41 were analysed for DFS as related to DIA,
since only two patients older than 40 maintained normal
menses. Thus, analysis was carried out on a small number of
cases, i.e. 19 non amenorrheic and 13 amenorrheic patients,
and the conclusion was that DFS was not affected by DIA.
The 10 year DFS was 31.6% and 37.2% for the two groups,
respectively. In addition, the same authors reported that
salvage castration at first relapse induced a higher response
rate in patients who had experienced DIA as compared to
those who had not (30% vs 20% response rate). Based upon
these findings they concluded that DIA is not equivalent to
complete ovarian failure; this opinion, based on a low
number of events, is contrasting with the data of others who
assessed ovarian function by measuring levels of circulating
sexual hormones during adjuvant chemotherapy (Koyama et
al., 1977; Fisher et al., 1979; Rose & Davis, 1980; Ludwig
Breast Cancer Study Group, 1985; Padmanabhan et al.,
1987), including ourselves (Delrio et al., 1986).
The National Surgical Adjuvant Breast Project group
(Fisher et al., 1979) reported a lack of association of DFS
with depressed ovarian function induced by melphalan. Since
improvement of DFS was slightly better in younger patients,
who had lower incidence of DIA, as compared to older
women, it was concluded that ovarian suppression could not
have played a role. However, no analysis was carried out to
evaluate the real relationship between occurrence of DIA and
effect of therapy.
By contrast, the Ludwig Group's Trial I (1985) showed
that amenorrhea induced by CMF-containing regimens was
significantly associated with a longer disease-free survival, in
younger patients, in patients who received lower CMF doses
and in patients with ER + tumours; it was, thus, suggested
that chemotherapy might influence tumour growth by sup-
pression of ovarian endocrine function, besides exerting a
direct cytotoxic effect.
Similarly, in the ECOG trial (Tormey et al., 1990) patients
developing DIA during adjuvant therapy with CMF, CMFP
or CMFPT had a highly significant better survival.
The Danish Breast Cancer Cooperative Group (Brincker et
al., 1987) found, in a prospective randomised trial, that
cyclophosphamide alone was effective in improving DFS only
in patients who experienced DIA, differently from CMF
which was active in DIA as well as in NA patients. It was
suggested that the effect of chemotherapy could be mediated
partly through ovarian suppression and partly through a
purely cytotoxic mechanism, the latter being more evident
when combination chemotherapy (CMF) was used.
Finally, in 1986, the Manchester group (Padmanabhan et
al., 1986) reported, in a randomised trial comparing CMF
with observation, that a significant improvement of 3-year
DFS and OS was seen only in premenopausal patients who
experienced CMF induced permanent amenorrhea: DFS of
CMF-treated non amenorrheic patients was similar to that of
untreated controls. However, recently the same group report-
ed in abstract form (Richards et al., 1990) that, at the 8-year
update of the study, the importance of DIA, in patients
younger than 41, has lessened. Since a full-length paper is not
available, it is difficult to discuss this result.
Our data show the existence of a significant correlation
between DIA and prolongation of DFS. The prognostic
relevance of DIA is independent of number of positive nodes,
tumour size and number of CMF cycles. These results are
consistent with those reported by the majority of studies that
could adequately document amenorrhea.
Although the existence of a strong statistical association
does not necessarily mean that DIA is causally related to a
better prognosis in early breast cancer, and amenorrhea
might only be a marker of a greater chemotherapy-induced
tumour cell kill (International Breast Cancer Study Group,
1990), our results strongly suggest that the suppression of
ovarian function could play a relevant role in the mechanism
of action of adjuvant cytotoxic therapy in premenopausal
breast cancer patients.
The beneficial effect of oophorectomy in both advanced
and early disease, the recent results with LHRH analogues,
which produce complete suppression of ovarian function, in
patients with advanced disease, the relationship between DIA
and improved DFS could suggest that adjuvant hormono-
therpay, e.g. LHRH superagonist ± Tamoxifen, might have
some effect in premenopausal patients. However, there is no
evidence that the effect of endocrine therapies will be as large
as chemotherapy. In fact, a recent paper of the International
Breast Cancer Study Group (Goldhirsch et al., 1990) shows
that chemotherapy provides additional cytotoxic effect over
and above those attributable to endocrine mechanisms alone.
Whether endocrine therapies can replace chemotherapy for
subset of premenopausal women with presumably hormone-
responsive primaries is a matter for future clinical trials.
We thank Dr G. Mezzanottea and Dr G. Valsecchi of the Institute
of Medical Statistics and Biometry, University of Milan, Italy, for
supplying the Mantel-Byar procedure software.
We also thank Dr Richard D. Gelber of the Department of
Biostatistics, Harvard School of Public Health, Boston, USA, and
Dr Michael K. Palmer, biometrics team leader of the ICI-Pharma for
kindly reviewing the manuscript and for their very pertinent com-
ments.
This work was supported by grants (86.00315.44, 87.01188.44,
88.00530.44) from the Italian 'Consiglio Nazionale delle Ricerche',
Finalized Project 'Oncologia' and from the 'Associazione Italiana per
la Ricerca sul Cancro' (AIRC).DRUG-INDUCED AMENORRHEA AND BREAST CANCER 803
References
ANDERSON, J.R., CAIN, K.C. & GELBER, R.D. (1983). Analysis of
survival by tumor response. J. Clin. Oncol., 1, 710.
BIANCO, A.R., DE PLACIDO, S., GALLO, C. & 5 others (1988). Adju-
vant therapy with tamoxifen in operable breast cancer. Lancet, fl,
1095.
BMDP STATISTICAL SOFTWARE (1988). Dixon, W.J. (ed.) Univer-
sity of California Press, Los Angeles.
BONADONNA, G., VALAGUSSA, P., ROSSI, A. & 4 others (1985).
Ten-year experience with CMF-based adjuvant chemotherapy in
resectable breast cancer. Breast Cancer Res. Treat., 5, 95.
BRINCKER, H., ROSE, C., RANK, F. & 5 others (1987). Evidence of a
castration-mediated effect of adjuvant cytotoxic chemotherapy in
premenopausal breast cancer. J. Clin. Oncol., 5, 1771.
BRYANT, A.J.S. & WEIR, J.A. (1981). Prophylactic oophorectomy in
operable instances of carcinoma of the breast. Surg. Gynecol.
Obstet., 153, 660.
COX, D.R. (1972). Regression models and life tables. J. R. Stat. Soc.
B, 34, 187.
DELRIO, G., DE PLACIDO, S., PAGLIARULO, C. & 10 others (1986).
Hypothalamic - pituitary - ovarian axis in women with operable
breast cancer treated with adjuvant CMF and tamoxifen. Tumori,
72, 53.
EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP
(1988). Effects of adjuvant Tamoxifen and of cytotoxic therapy
on mortality in early breast cancer. N. Engi. J. Med., 319, 1681.
EDITORIAL (1989). Adjuvant systemic treatment for breast cancer
meta-analysed. Lancet, i, 80.
FISHER, B., SHERMAN, B., ROCKETTE, H., REDMOND, C., MARGO-
LESE, R. & FISHER, E.R. (1979). I-Phenylalanine mustard (L-
PAM) in the management of premenopausal patients with
primary breast cancer. Lack of association ofdisease-free survival
with depression of ovarian function. Cancer, 44, 847.
GOLDHIRSCH, A., GELBER, R.D & CASTIGLIONE, M. (1990). The
magnitude of endocrine effects of adjuvant chemotherapy for
premenopausal breast cancer patients. Ann. Oncol., 1, 183.
INTERNATIONAL BREAST CANCER STUDY GROUP (1990). Late
effects of adjuvant oophorectomy and chemotherapy upon pre-
menopausal breast cancer patients. Ann. Oncol., 1, 30.
KAPLAN, E.L. & MEIER, P. (1958). Nonparametric estimation from
incomplete observation. J. Am. Stat. Assoc., 53, 457.
KOYAMA, H., WADA, T., NISHIZAWA, Y. & 6 others (1977). Cyclo-
phosphamide-induced ovarian failure and its therapeutic signi-
ficance in patients with breast cancer. Cancer, 39, 1403.
LUDWIG BREAST CANCER STUDY GROUP (1985). A randomized
trial of adjuvant combination chemotherapy with or without
prednisone in premenopausal breast cancer patients with metas-
tases in one to three axillary lymph nodes. Cancer Res., 45, 4454.
MANTEL, N. (1966). Evaluation of survival data and two new rank
order statistics arising in its consideration. Cancer Chem. Rep.,
50, 163.
MANTEL, N. & BYAR, D.P. (1974). Evaluation of response-time data
involving transient states: an illustration using heart transplant
data. J. Am. Stat. Assoc., 69, 81.
MEAKIN, J.W., ALLT, W.E.C., BEALE, F.A. & 10 others (1983).
Ovarian irradiation and prednisone following surgery and radio-
therapy for carcinoma of the breast. Breast Cancer Res. Treat., 3
(Suppl. 1), 45.
NISSEN-MEYER, R. (1967). The role of prophylactic castration in the
therapy of human mammary cancer. Eur. J. Cancer, 3, 395.
PADMANABHAN, N., HOWELL, A. & RUBENS, R.D. (1986). Mechan-
ism of action of adjuvant chemotherapy in early breast cancer.
Lancet, ii, 411.
PADMANABHAN, N., WANG, D.Y., MOORE, J.W. & RUBENS, R.D.
(1987). Ovarian function and adjuvant chemotherapy for early
breast cancer. Eur. J. Cancer Clin. Oncol., 23, 745.
RICHARDS, M.A. O'REILLY, S.M., HOWELL, A. & RUBENS, R.D.
(1990). Adjuvant CMF in node positive breast cancer: Guy's/
Manchester trial at 8 years. Proc. Am. Soc. Clin. Oncol., 9, 18.
ROSE, D.P. & DAVIS, T.E. (1980). Effects ofadjuvant chemohormonal
therapy on the ovarian and adrenal function of breast cancer
patients. Cancer Res., 40, 4043.
SIMON, R. & MAKUCH, R.W. (1984). A non-parametric graphical
representation of the relationship between survival and the occur-
rence of an event: application to responder versus non-responder
bias. Stat. Med., 3, 35.
TORMEY, D.C., GRAY, R., GILCHRIST, K. & 5 others (1990).
Adjuvant chemohormonal therapy with cyclophosphamide,
methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP
plus tamoxifen compared with CMF for premenopausal breast
cancer patients. An Eastern Cooperative Oncology Group Trial.
Cancer, 65, 200.